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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor 
prognosis due to resistance to conventional chemotherapy and limited efficacy of radiotherapy. There is an urgent 
need to develop novel biomarkers for early diagnosis, as well as to identify new drug targets for therapeutic 
interventions.
Patients and methods: 54 paired HCC samples and 21 normal liver tissues were obtained from West China Hospital of 
Sichuan University. Informed consent was obtained from all the patients or their relatives prior to analysis, and the 
project was approved by the Institutional Ethics Committee of Sichuan University. Stable Isotope Labeling with Amino 
Acids in Cell Culture (SILAC)-based proteomics was employed to profile the differentially expressed proteins between a 
HepG2 human hepatoma cell line and an immortal hepatic cell line L02. Validation of PGAM1 expression was 
performed by semi-quantitative RT-PCR, immunoblot and immunohistochemistry using clinical samples. shRNA 
expressing plasmids specifically targeting PGAM1 were designed and constructed by GenePharma Corporation 
(Shanghai, China), and were utilized to silence expression of PGAM1 in vitro and in vivo. Cell proliferation was measured 
by a combination of colony formation assay and Ki67 staining. Apoptosis was examined by flow cytometry and TUNEL 
assay.
Results: A total of 63 dysregulated proteins were identified, including 51 up-regulated proteins, and 12 down-
regulated proteins (over 2-fold, p < 0.01). Phosphoglycerate mutase 1 (PGAM1) was found markedly upregulated. 
Clinico-pathological analysis indicated that overexpression of PGAM1 was associated with 66.7% HCC, and strongly 
correlated with poor differentiation and decreased survival rates (p < 0.01). shRNAs-mediated repression of PGAM1 
expression resulted in significant inhibition in liver cancer cell growth both in vitro and in vivo.
Conclusion: Our studies suggested that PGAM1 plays an important role in hepatocarcinogenesis, and should be a 
potential diagnostic biomarker, as well as an attractive therapeutic target for hepatocellular carcinoma.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide with poor prognosis, and is
responsible for 600 000 deaths annually worldwide [1-5].
Many patients are diagnosed at the advanced stage and
missed the best opportunity for effective therapy, such as
liver resection, or transplantation. On the other hand,
patients who were resected often have a high frequency
of metastasis/recurrence, and postoperative 5-year sur-
vival is only 30%-40% [6]. Moreover, liver transplantation
is not applicable universally because of the shortage of
organ donations and occurrence of relapse [7]. Conse-
quently, there is an urgent need to screen for novel thera-
peutic targets.
The metabolism of cancer cells differs significantly
from that of normal cells [8]. Cancer cells are able to
maintain high rates of aerobic glycolysis even under the
high-oxygen (20%) conditions of normal tissue culture.
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This property, known as the "Warburg effect", has been
recognized for over 70 years [9,10]. In this context, main-
taining a high level of glycolysis is indispensable for sur-
vival and growth of cancer cells [11]. Guided by this
principle, intervention with cellular glucose utilization
could lead to a significant inhibition of cell growth,
induction of cell death, stimulating migration of key
enzymes out of the glycolytic enzyme complexes as well
[12,13]. Recently, chemistry-based functional proteomics
was applied to screen for drug target against breast can-
cer, and phosphoglycerate mutase 1 (PGAM1) was identi-
fied as a novel metabolic enzyme involved in breast
carcinogenesis [14].
In adult mammals, three isozymes of PGAM are pres-
ent which result from the homo- and heterodimeric com-
binations of two different 30-kD subunits, M and B,
encoded by two different genes [15,16]. The homodimer
BB-PGAM (a brain form; PGAM1 in human), is
expressed mainly in liver, kidney, and brain; the homodi-
mer MM-PGAM (muscle-specific form; PGAM2 in
human), is mainly found in the mature muscle cells; and
the heterodimer MB-PGAM, mainly exists in heart [16-
18]. Particularly, PGAM1, a key enzyme of the glycolytic
pathway, converts 3-phosphoglycerate to 2-phosphoglyc-
erate with 2, 3-bisphosphoglycerate (2, 3-BPG) as a cofac-
tor of the reaction to release energy which is essential for
cell growth [19]. Several investigations demonstrated that
PGAM1 was overexpressed in a variety of human can-
cers, including breast carcinoma [14,20]; colorectal can-
cer [21,22]; lung cancer [23,24]; prostate cancer [19]; oral
squamous cell carcinoma [25]; esophageal squamous cell
carcinomas [26]; and also associated with certain virus
infection [27,28]. Overexpression of PGAM1 can immor-
talize mouse embryonic fibroblasts and promote cell pro-
liferation, suggesting its potential oncogenic property
[10]. Furthermore, a recent study showed that a PGAM1
peptide inhibitor induced cancer cell growth arrest in
breast carcinoma [14]. Taken together, targeting the
PGAM1 may be preferentially lethal to the malignant
cells and have potentially broad clinical and therapeutic
implications.
In the present study, we utilized a quantitative pro-
teomic approach to profile the altered expressed proteins
between a liver cancer cell line HepG2, and an immortal-
ized human normal hepatocyte cell line L02. Of the 63
dysregulated proteins, we found that PGAM1 was signifi-
cantly upregulated. Clinicopathological analyses revealed
that overexpression of PGAM1 was closely associated
with hepatocarcinogenesis. The data presented in this
study suggested that PGAM1 could be developed as a
useful diagnostic biomarker, as well as a potential thera-
peutic target for hepatocellular carcinoma.
Experimental Procedures
Clinical specimens
Paraffin-embedded HCC and the adjacent normal tissues
were obtained from 54 patients who underwent surgical
resections at the West China Hospital of Sichuan Univer-
sity (Chengdu, China). Histodifferentiation grading of
specimens was assigned according to Edmondson Steiner
grading by experienced pathologists. 21 normal liver
specimens were collected from patients undergoing sur-
gical resections for hepatic cyst or calculus of intrahe-
patic duct. The surgical pathologic staging was assigned
according to the modified UICC classification [29]. A
summary of detailed clinicopathologic information for
these patients was shown in Table 1. Each tissue was cut
into two parts: one part was snap frozen for immunoblot
and RT-PCR validation, and the other part was fixed in
formalin for immunohistochemistry analysis. Informed
Table 1: Clinicopathologic features of all patients.
Clinicopathologic Features Number Mean Agea(%)
Normal liver tissues 21 45.4 ± 5.7
Hepatocellular carcinoma 54 44.8 ± 8.5 (100.0)
Histodifferentiation grading
Well differentiated 11 45.2 (20.4)
Moderately differentiated 28 40.6 (51.9)
Poorly differentiated 15 46.4 (27.8)
Surgical pathologic staging
I 14 48.1 (25.9)
II 21 43.9 (38.9)
III 9 46.1 (16.7)
IV 10 45.3 (18.5)
a Mean age in years.Ren et al. Molecular Cancer 2010, 9:81
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consent was obtained from all the patients or their rela-
tives prior to analysis, and the project was approved by
the Institutional Ethics Committee of Sichuan University.
Cell culture, SILAC labeling and transfection
Human hepatoma cell line HepG2 was purchased from
ATCC (Rockville, MD, USA) and maintained in Dul-
becco's modified Eagle's medium (DMEM, Gibco, USA)
supplemented with 10% fetal calf serum (Hyclone, USA),
penicillin (107U/L) and streptomycin (10 mg/L) at 37°C in
a 5% CO2 atmosphere. Human immortalized normal liver
cell line L02 was obtained from China Cell Culture Cen-
ter (Shanghai, China) and cultured in Dulbecco's modi-
fied Eagle's medium (DMEM, Gibco, USA) [30].
For SILAC-labelling, cells were grown in SILAC™ D-
MEM (Invitrogen, USA) containing 10% v/v dialysed FBS,
2 mM L-glutamine, and either 0.1 mg/mL SILAC™ light
[12C6] or SILAC™ heavy [13C6] L-lysine (Invitrogen). To
ensure full incorporation of the heavy and light labeled
amino acids, cells were grown for at least six cell dou-
blings prior to analysis.
For transient transfection, HepG2 cells were seeded in
6- or 96-well culture plates at a density of 105 cells or 5000
cells/well, respectively. After incubated overnight, cells
were transfected with PGAM1-shRNA (2 μg/well) or the
scramble shRNA using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer's instruc-
tions.
Protein preparation and SDS-PAGE separation
Equal amounts of protein from HepG2 (13C6-lysine) and
L02 (12C6-lysine) cell lines were mixed (60 μg in total),
b o i l e d  i n  S D S - P A G E  s a m p l e  b u f f e r ,  r e s o l v e d  b y  S D S -
PAGE and stained with Coomassie Brilliant Blue R-250
(Merck, Germany).
In-gel trypsin digestion
In-gel digestion was performed using mass spectrometry
grade Trypsin Gold (Promega, Madison, WI, USA)
according to the manufacturer's instructions. Briefly, the
excised gel slices were destained twice with 100 mM
NH4HCO3/50% acetonitrile at 37°C for 45 min, and dried
in a centrifugal vacuum concentrator, followed by a pre-
incubation in 10-20 μl trypsin solution for 1 h. Subse-
quently the digestion buffer were added (40 mM
NH4HCO3/10% ACN) to cover the gel pieces and incu-
bated overnight at 37°C. Tryptic digests were extracted
twice with 50% ACN/5% trifluoroacetic acid (TFA) for 1
h each time. The combined extracts were dried in a vac-
uum concentrator to a final volume of 5 μl at room tem-
perature. The samples were then subjected to mass
spectrometric analysis.
Protein identification and quantitation by LC-MS/MS
Mass spectra were acquired using a LC-MS mass spec-
trometer (Micromass, Manchester, UK). Tryptic digests
were dissolved in 20 μl of 50% ACN. The automatic scan
rate was 1.0 s with an interscan delay of 0.02 s, and the
voltage was operated at 3.0 KV. Spectra were accumu-
lated until a satisfactory signal/noise ratio had been
obtained with the range 400 - 1600 m/z picked out for
LC-MS/MS analysis. The collision energy was varied
between 18 - 57 eV depending on the mass of the precur-
sor. Quantitation was carried out by SILCA K+ 6 R+ 10
[MD]. The MS/MS data, "pkl list" files were acquired by
the software ProteinLynx 2.2.5 software (Waters), which
include the mass values, the intensity and the charge of
the precursor ions (parent ions with +1, +2 or +3 charges
in this study). The pkl files were analyzed using the MAS-
COT search engine against the Swiss-Prot protein data-
base. The search parameters were carried out as follows:
Database, Swiss-Prot; taxonomy, homo sapien; enzyme,
trypsin; and an allowance of one missed cleavage. Carb-
amidomethylation was set as a fixed modification and
oxidation of methionine was variable. The peptide and
fragment mass tolerance were both set at 0.2 Da. Proteins
were identified at least one peptide exceeding their score
threshold (p < 0.01) and with their MW and pI consistent
with the gel regions from which the bands were excised
indicated the 95% confidence level for the matched pep-
tides. Protein intensity alteration (>2 fold) was defined as
dysregulation.
Semi-quantitative RT-PCR
The following primer sequences were used to detect
PGAM1 transcripts: sense (5'-GCACCCACTCCCT-
TCATACAAT-3') and antisense (5'-ACGCAGGTTA-
CATTCGTCTTCC-3'). Total RNA was extracted using
Trizol Reagent (Invitrogen, USA). RT-PCR reaction was
performed as follows: reverse transcription at 45°C for 30
min and denaturation at 94°C for 2 min; then amplifica-
tion for 30 cycles at 94°C for 30 s, annealing at 54°C for 1
min, and extension at 72°C for 1.5 min, followed by a ter-
minal elongation step at 72°C for 10 min and a final hold-
ing stage at 4°C. PCR products were resolved by 1%
agarose gel electrophoresis.
Western blotting analysis
Western blotting analysis was performed as described
elsewhere [31]. Briefly, 30 μg of proteins were separated
by 12% SDS-PAGE and transferred to PVDF membranes
(Amersham Biosciences). After blocking overnight with
TBS/T containing 0.1% Tween 20 in 5% skimmed milk at
4°C, the membranes was subsequently probed with pri-
mary antibody PGAM1 (diluted 1:1000, Abcam) for 2 h at
RT and washed 3 times in TBS/T. Subsequently the mem-
branes were incubated with secondary antibody conju-Ren et al. Molecular Cancer 2010, 9:81
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gated to Horseradish Peroxidase for 2 h at RT.
Immunoblot was detected by the enhanced chemilumi-
nescence (ECL) detection system (Pierce Biotech Inc.,
Rockford, IL, USA).
Immunohistochemistry analysis
Tissues were formalin-fixed and Paraffin-embedded, and
sections were consecutively cut into 3-4 μm thickness for
immunohistochemistry (IHC) analysis using a Dako
EnVision System (Dako Cytomation GmbH, Hamburg,
Germany Denmark) according to the manufacturer's
instructions. Briefly, the paraffin-sections were dewaxed,
rehydrated, and incubated in 3% H2O2 for 10 min in dark
at room temperature to quench the endogenous peroxi-
dase activity. Antigen retrieval was performed in citrate
buffer (pH 6.0) using autoclave sterilizer method. Subse-
quently, the sections were blocked by normal rabbit or
goat serum diluted in PBS (pH 7.4) for 20 min at 37°C,
followed by an incubation at 4°C overnight with the pri-
mary antibodies, either goat anti-PGAM1 (diluted 1:150,
Abcam, Cambridge, UK) or mouse anti-Ki67 (diluted
1:200, Santa Cruz Biotechnology, Santa Cruz, CA). After
rinse in fresh PBS for 15 min, slides were incubated with
horseradish peroxidase-linked rabbit anti-goat and anti-
mouse antibodies at 37°C for 40 min, followed by reaction
with 3,3'-diaminobenzidine substrate solution (Dako
Cytomation GmbH) and counterstaining with Mayer's
hematoxylin. The immunohistochemical staining was
assessed by calculating the percentage of positive hepato-
cytes and the immunostaining intensity [32]. Slides were
examined separately by two independent pathologists
with no prior knowledge of each patient's clinical and
pathological parameters. Any discrepancy between the
two evaluators was resolved by reevaluation and careful
discussion until agreement was reached.
Cell proliferation and apoptosis assay
Upon treatment, cells were incubated at 37°C for indi-
cated durations. Cell proliferation was measured by
means of MTT assay according to the manufacturer's
instructions. 20 μl MTT (2 mg/ml, Sigma, St. Louis, MO)
was added in the media and incubated for another 2 h.
The media was removed and formazan precipitate was
dissolved in 150 μl Dimethyl Sulfoxide (DMSO, Amresco,
Solon, Ohio, USA). Ten minutes later, absorbance values
were measured at 595 nm wavelength on a Spectra Max
M5 (MDC, Sunnyrale, VA, USA).
For colony formation assay, cells were seeded in 6-well
plates at a density of 300 cells per well. Assay was per-
formed at 24 h posttransfection, cells were cultured for
a n o t h e r  t w o  w e e k s .  C o l o n i e s  w e r e  w a s h e d  w i t h  P B S ,
fixed with methanol and stained with Crystal Violet
(Sigma, St. Louis, MO, USA). Cells were counted under a
micr oscope and a cluster wit h more than 50 c e lls was
considered as a clone.
For flow cytometric analysis, cells were trypsinized and
washed with 0.9% NaCl at 72 h post transfection, and
then fixed with 70% ethanol at 4°C overnight. Cells were
incubated with staining solution (5 μg/ml propidium
iodide, 20 μg/ml Rnase A) in dark at room temprature for
1 h. The stained cells were analyzed on an EPICS ELITE
ESP flow cytometer (Beckman Coulter, USA).
TUNEL staining was performed using terminal deoxy-
nucleotidyl transferase (Promega Inc., Madison, WI,
USA). Cells were fixed in freshly prepared 4% methanol-
free formaldehyde solution in PBS (pH 7.4) for 25 min-
utes at 4°C, washed with fresh PBS for 10 minutes at
room temperature and permeabilized in 0.2% Triton-100
solution in PBS for another 5 min. After equilibration for
10 min, the cells were incubated with rTdT buffer and
observed under a fluorescence microscope, and a nucleus
with bright green fluorescence staining was recorded as a
TUNEL-positive event (Olympus Optical Co, Hamburg,
Germany).
Tumor xenograft model and shRNA treatment
The cDNA sequence of PGAM1 was obtained from Gen-
bank (NM_002629). Three PGAM1-specific short hair-
pin RNAs (shRNAs) were designed based on the rules as
described elsewhere [33]. As shown in Table S1, addi-
tional file 1, shRNA expressing plasmids specifically tar-
geting PGAM1 (termed as PGAM1-shRNA-a, -b and -c)
were constructed by GenePharma Corporation (Shang-
hai, China) using pGPU6/GFP/Neo vector. An unrelated
shRNA sequence (HK), with no homology to any human
gene, was used as a negative control (shNC).
For animal study, 6-8 weeks old female nude mice
(BALB/c, 18-20 g body weight) were injected subcutane-
ously with HepG2 cell suspensions about 2 × 106 cells/100
μl/mouse in PBS via the right flank. When the tumor
diameter reached about 6 mm, the tumor-bearing mice
were randomly divided into four experimental groups (n
= 5 mice/group): 1) PBS: 100 μl/mouse; 2) LIPO: Lipo-
fectamine 2000 at 12.5 μl/100 μl of PBS; 3) shNC (nega-
tive control): 5 μg/100 μl of PBS; 4) PGAM1-shRNA-a: 5
μg/100 μl of PBS. Tail intravenous injections were per-
formed every two days, and the tumor volumes were
evaluated by the following formula: tumor volumes
(mm3) = π/6 × length × width2. The tumor growth inhibi-
tion in the presence or absence of PGAM1 shRNA has
been monitored for 20 days until the mice were sacri-
ficed. The tumor tissues were formalin-fixed and paraf-
fin-embedded for immunohistochemistry. All animals
received humane care according to the Institutional Ani-
mal Care and Treatment Committee of Sichuan Univer-
sity.Ren et al. Molecular Cancer 2010, 9:81
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Statistics
All quantitative data were recorded as mean ± S.D. Com-
parisons between two groups were performed by Stu-
dent's  t  test. Differences among multiple groups were
assessed by one-way ANOVA analysis, LSD-t test. Rele-
vance analysis of ordinal data was performed by cross χ2
test. Statistical significance was defined as p < 0.05.
Results
Proteomic profiling of the differentially expressed proteins 
between HepG2 and LO2 by SILAC
Differentially expressed proteins were defined as statisti-
cally significant based on two criteria: 1) intensity altera-
tions >2.0-fold (Student's t  test,  p  < 0.05) and 2)
recurrence more than two times in the 3 repeated experi-
ments. According to these criteria, a total of 63 distinct
proteins were identified by LC-MS/MS, as listed in Table
2. Cluster analysis revealed that the altered proteins were
involved in diverse biological processes, including metab-
olism (34.9%), signal transduction (12.7%), structural
component (7.9%) and others (44.5%) (Fig. 1A and 1B).
Among them, PGAM1 was identified with most signifi-
cant alteration that PGAM1 was up-regulated over 6-fold
in HepG2 cells compared to L02 cells (p < 0.01). Further,
LC MS/MS analysis revealed eight matched peptides,
with 38% sequence coverage and a MOWSE score of 172
(Fig. 1, C-F). The housekeeping gene β-actin was always
selected to monitor the labeling status.
Overexpression of PGAM1 in HCC
To examine if PGAM1 was overexpressed in HCC, a vali-
dation experiment was carried out. A total of 54 paired
liver cancer tissues were collected, and expression of
PGAM1 was compared at both transcriptional and trans-
lational levels between HCC tissues and the correspond-
ing adjacent noncancerous tissues. As shown in Fig. 2A,
the transcripts of PGAM1 were much higher in HCC,
compared with the noncancerous tissues. Further immu-
noblot analysis was performed using anti-PGAM1 anti-
body, and overexpression of PGAM1 was observed in
66.7% (36/54) of the HCC tissues (Student's t test, p <
0.01). Together, our data demonstrated that PGAM1 is
overexpressed in HCC tissues at both mRNA and protein
levels, which is consistent with the observation in the
quantitative proteomic analysis (Fig. 2B and 2C).
Overexpression of PGAM1 was correlated with poor 
prognosis of HCC
To further investigate the potential oncogenic properties
of PGAM1 in hepatocarcinogenesis, immunohistochem-
istry was performed to examine PGAM1 expression in
paraffin-embedded tissues. 54 pairs of HCC tissues at dif-
ferent clinicopathologic stages and 21 normal liver tissues
were prepared for immunohistochemical analysis. Of the
54 HCC samples (mean age, 44.8 ± 8.5 years), 11 were
well differentiated, 28 were moderately differentiated,
and 15 were poorly differentiated; 14 were in staging I, 21
were in staging II, 9 were in staging III, and 10 were in
staging IV according to Surgical Pathologic Staging Crite-
ria (6th Edition, 2002) (Table 1). In 54 paired HCC sam-
ples, no or weakly positive staining could be detected in
19 and 81% of non-tumor liver tissues, respectively (Table
3). By contrast, in tumor tissues, weakly positive staining
was observed in 24% (13/54), moderately positive stain-
ing was about 35% (19/54) and the strong positive stain-
ing was 41% (22/54) (Table 4). As shown in Fig. 3A, the
staining intensity and the number of positively stained
cells were markedly different between normal and hepa-
toma tissues (p < 0.01). Overexpression of PGAM1 was
more likely to be present with poor differentiation (p <
0.05).
To assess the correlation between overexpression of
PGAM1 and the survival rates, 54 patients were retro-
spectively studied (Fig. 3B). The five year survival rates
were 55.6%, 28.6%, 18.2% for weakly positive, positive and
strongly positive staining samples, respectively. In order
to evaluate whether PGAM1 could be utilized as an inde-
pendent prognostic factor associated with clinical out-
come of HCCF, multivariate analyses were carried out
using Cox proportional hazard model. The risk variables
examined included PGAM1 immunoreactivity (weakly/
m o d e r a t e l y  c o m p a r e d  w i t h  s t r o n g l y  p o s i t i v e ) ,  a g e  o f
patients (>50 compared with ≤50 years), histodifferentia-
tion (weak/moderate compared with poor differentia-
tion), and surgical pathologic staging (staging I, II, III
compared with IV). Our studies suggested that PGAM1
could be developed as an independent prognostic factor
for HCC.
Suppression of liver cancer cell Proliferation by PGAM1-
shRNA
In a pilot study, three shRNA expressing plasmids target-
ing PGAM1 were designed (termed as PGAM1-shRNA-
a, b, c), and their silencing effects were evaluated in
HepG2 cells. Our data demonstrated that the expression
of PGAM1 was remarkably reduced when HepG2 cells
were treated with either PGAM1-shRNA-a or PGAM1-
shRNA-b whilst no apparent silencing effect could be
observed if HepG2 cells were treated with PGAM1-
shRNA-c, compared with the negative control shNC (See
additional file 1; Fig.S1).
To investigate the potential function of PGAM1, the
liver cancer cell line HepG2 was treated with PGAM1-
shRNA. As shown in Fig. 4A, PGAM1 knockdown by
PGAM1-shRNA-a resulted in remarkable inhibition of
liver cancer cell proliferation, which was demonstrated by
both MTT and clonogenic formation assays. MTT data
showed that cell proliferation was suppressed byR
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Table 2: Proteins identified by LC MS/MS.
Protein namea Gene name Accession no.b Theotetical 
molecular mass/PIc
Queries matched Sequence
coverage (%)
MOWSE scored Fold changee Function
Up-regulation
Macrophage migration inhibitory factor MIF P14174 12642/7.74 1 9 57 3.1 ± 0.9 Immune regulation
Peptidyl-prolyl cis-trans isomerase A PPIA P62937 18233/7.68 12 35 238 8.7 ± 2.2 Protein folding
Eukaryotic translation initiation factor 5A-1 IF5A1 P63241 17053/5.08 3 22 214 2.1 ± 0.9 Translation regulation
Histone H2A.V H2AV Q71UI9 13501/10.58 2 28 138 3.9 ± 1.1 Transcription regulation
Phosphatidylethanolamine-binding protein 1 PEBP1 P30086 21160/7.01 2 18 92 2.9 ± 0.9 Signal transduction
Peroxiredoxin-6 PRDX6 P30041 25135/6.00 8 40 175 3.1 ± 1.2 Metabolism
Phosphoglycerate mutase 1 PGAM1 P18669 28902/6.67 8 38 172 6.0 ± 1.4 Metabolism
14-3-3 protein zeta/delta 1433Z Q6P3U9 27902/4.73 9 33 126 3.3 ± 1.2 Signal transduction
Triosephosphate isomerase TPIS P60174 26943/6.45 21 45 406 2.9 ± 0.8 Metabolism
Proteasome activator complex subunit 1 PSME1 Q06323 28879/5.78 1 7 59 6.7 ± 2.1 Proteolysis
Enoyl-CoA hydratase, mitochondrial ECHM P30084 31831/8.34 1 7 51 2.6 ± 0.8 Metabolism
Annexin A4 ANXA4 P09525 36092/5.84 1 5 98 2.4 ± 0.5 Signal transduction
Annexin A5 ANXA5 P08758 35972/4.94 2 8 52 3.7 ± 1.5 Signal transduction
Aldo-keto reductase family 1 member C1 AK1C1 Q04828 37229/8.02 4 24 109 11.7 ± 2.7 Metabolism
Aldo-keto reductase family 1 member C3 AK1C3 Q9UKL9 37227/8.05 2 10 58 8.1 ± 2.4 Metabolism
Alpha-enolase ENOA Q6GMP2 47487/7.01 20 27 485 7.8 ± 1.9 Metabolism
Keratin, type I cytoskeletal 19 K1C19 Q9P1Y4 44065/5.04 17 32 344 5.8 ± 1.9 Structural component
Keratin, type I cytoskeletal 18 K1C18 P05783 48029/5.34 17 12 285 5.1 ± 1.7 Structural component
Phosphoglycerate kinase 1 PGK1 P00558 44992/8.30 6 13 73 18.3 ± 4.3 Metabolism
Isocitrate dehydrogenase [NADP] cytoplasmic IDHC O75874 46920/6.53 1 3 53 2.6 ± 0.3 Metabolism
Keratin, type II cytoskeletal 8 K2C8 Q96J60 53671/5.52 18 26 273 5.1 ± 1.3 Structural component
60 kDa heat shock protein, mitochondrial CH60 P10809 61190/5.70 18 23 477 10 ± 3.4 Molecular chaperone
UDP-glucose 6-dehydrogenase UGDH O60701 5685/6.73 2 8 75 3.1 ± 1.1 Metabolism
Glutamate dehydrogenase 1 GLUD1 P00367 61701/7.66 4 26 187 8.3 ± 2.6 Metabolism
Aminoacylase-1 ACY1 Q03154 46084/5.77 6 25 246 4.7 ± 1.9 Proteolysis
Glutathione transferase omega-1 GSTO1 P78417 27833/6.24 7 18 264 8.3 ± 2.4 Metabolism
Ubiquitin UBC P62988 8560/6.56 7 9 156 2.7 ± 0.8 Proteolysis
Cofilin-1 COF1 P23528 18723/8.22 6 27 306 2.6 ± 1.1 Signal transduction
Acidic leucine-rich nuclear phosphoprotein 32 family 
member B
AN32B Q92688 28944/3.94 4 19 136 4.1 ± 1.4 Protein binding
Annexin A3 ANXA3 P12429 36527/5.63 3 12 85 13.5 ± 2.7 Signal transduction
Histone H1.2 H12 P16403 21352/10.94 3 6 54 9.5 ± 2.4 Protein binding
Glyceraldehyde-3-phosphate dehydrogenase G3P P04406 36204/8.57 63 59 1299 8.1 ± 2.7 Metabolism
Aldose reductase ALDR P15121 36237/6.51 11 25 240 8.5 ± 3.1 Protein bindingR
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Aldo-keto reductase family 1 member C2 AK1C2 P52895 37118/7.13 5 20 229 14.8 ± 4.5 Metabolism
Aldo-keto reductase family 1 member B10 AK1BA O60218 36230/7.12 3 13 131 13.1 ± 3.8 Metabolism
Complement component 1 Q subcomponent-
binding protein, mitochondrial
C1QBP Q07021 31749/4.74 2 10 78 13.3 ± 3.7 Immune regulation
60S ribosomal protein L6 RL6 Q02878 32766/10.59 11 26 202 11.3 ± 3.7 Transcription regulation
Poly(rC)-binding protein 2 PCBP2 Q15366 38962/6.33 3 13 62 10.2 ± 2.4 Protein binding
Heat shock 70 kDa protein 1 HSP71 P08107 70299/5.48 4 8 115 20.4 ± 4.8 Molecular chaperone
Trifunctional enzyme subunit alpha, mitochondrial ECHA P40939 83701/9.16 4 8 98 3.8 ± 1.9 Metabolism
Annexin A6 ANXA6 P08133 76174/5.42 4 3 92 11.4 ± 3.2 Signal transduction
Heat shock 70 kDa protein 1L HS71L P34931 70737/5.76 4 6 84 29.5 ± 5.7 Molecular chaperone
Protein disulfide-isomerase A4 PDIA4 P13667 73235/4.96 3 4 81 11.4 ± 3.6 Metabolism
ATP synthase subunit beta, mitochondrial ATPB P06576 56525/5.26 14 28 352 22.7 ± 4.9 Metabolism
Pyruvate kinase isozymes M1/M2 KPYM Q9BWB5 58480/7.96 12 23 334 2.3 ± 1.4 Metabolism
Protein disulfide-isomerase PDIA1 P07237 57487/4.76 3 5 84 8.8 ± 3.6 Protein binding
Delta-1-pyrroline-5-carboxylate synthetase P5CS P54886 88002/6.66 6 6 178 14.3 ± 4.1 Metabolism
Desmoplakin DESP P15924 334063/6.44 3 2 64 3.3 ± 1.6 Structural component
ATP-dependent DNA helicase 2 subunit 2 KU86 P13010 83232/5.55 3 7 53 9.6 ± 3.5 Protein binding
Cullin-associated NEDD8-dissociated protein 1 CAND1 Q9P0H7 138029/5.52 6 3 63 4.1 ± 2.1 Transcription regulation
ATP-dependent DNA helicase 2 subunit 1 KU70 P12956 70089/6.23 9 5 107 3.1 ± 1.6 Protein binding
Down-regulation
Protein S100-A6 S100A6 P06703 10231/5.33 2 28 53 3.8 ± 1.4 Calcium ion binding
Calpain small subunit 1 CAPNS1 P04632 28469/5.05 4 13 157 3.1 ± 1.6 Calcium ion binding
Annexin A1 ANXA1 P04083 38922/6.57 2 4 98 2.7 ± 0.8 Calcium ion binding
Interleukin-18 precursor (IL-18) IL18 Q14116 22597/4.54 12 18 123 2.3 ± 0.6 Immune regulation
Transketolase TKT P29401 68531/7.58 9 13 145 6.2 ± 1.9 Metabolism
Profilin-1 PFN1 P07737 15219/8.44 6 21 140 3.4 ± 1.7 Structural component
Pyruvate dehydrogenase E1 component alpha 
subunit
PDHA1 P08559 43296/8.35 14 8 179 3.5 ± 1.5 Metabolism
Protein SET SET Q01105 33469/4.23 2 16 96 4.4 ± 1.7 Signal transduction
Heat shock protein HSP 90-alpha HS90A P07900 85013/4.94 40 26 428 2.8 ± 0.5 Molecular chaperone
Histone H2A type 2-A H2A2A Q6FI13 14087/10.90 6 36 153 3.7 ± 1.2 Transcription regulation
Poly(rC)-binding protein 1 PCBP1 Q15365 37996/6.66 9 17 118 2.6 ± 1.4 Protein binding
Lamin-A/C LMNA P02545 74385/6.57 7 11 86 3.7 ± 1.8 Protein binding
a For several proteins, a few isoforms were identified in the same individual.
b Accession numbers were derived from the ExPASy database.
c Theoretical molecular mass (kDa) and pI from the ExPASy database.
d Probability-based MOWSE (molecular weight search) scores.
e Expression change level in HepG2 cells compared with L02 cells.
Table 2: Proteins identified by LC MS/MS. (Continued)Ren et al. Molecular Cancer 2010, 9:81
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Figure 1 Identification and quantification of proteins by LC-MS/MS Based on SILAC method. (A) Clustering analysis of the identified proteins 
from L02 cells and HepG2 cells. Protein cluster map generated by Cluster software. Expression of proteins in the normal group was constant at 0, pro-
teins up-regulated in cancer tissue were in red, and the down-regulated proteins were in green. The intensity of the color green or red corresponds 
to the degree of alteration, respectively, according to the color strip at the bottom of the figure. These data were derived from three independent 
analyses. (B) A total of 63 dysregulated proteins were classified into 11 groups with diverse functions including metabolism (34.9%), signal transduc-
tion (12.7%), structural component (7.9%), and other functions (44.5%). (C), (D), and (E) showed output of the LC MS/MS database using the MASCOT 
program. LC MS/MS analysis revealed 8 matched peptides with 38% sequence coverage and a MOWSE score of 172. The matched peptides were 
shown in bold red. (F), left, MS spectrum showed a SILAC peptide matching PGAM1, with an up-regulation up to 6-fold. The m/z presents a difference 
of 3 mass units between labeled and unlabeled peptide pair, resulting in a 2+ change state; right, control SILAC peptide from β-actin.Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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PGAM1-shRNA-a in duration-dependent manner, and
the proliferation ratio was decreased by 48.6% at 72 h
posttransfection, compared to the negative control
(shNC). In colony formation assay, upon 14-day continu-
ous culture, the clone numbers were 92 ± 3.84, 69 ± 3.38,
and 65 ± 4.33 in untreated control, mock control (Lipo-
fectamine 2000), and negative control (shNC), respec-
tively (Fig. 4A). Meanwhile the clone number in the
PGAM1-siRNA-a group was 25 ± 3.02 with an inhibition
ratio of 72.8% (Dunnett's t test, p < 0.01) (Fig. 4B).
Knockdown of PGAM1 expression induced cancer cell 
apoptosis
To examine if loss of PGAM1 expression induces apop-
totic cell death, flow cytometric analysis was performed
to measure the sub-G1 value of HepG2 liver cancer cell
Figure 2 Overexpression of PGAM1 in HCCs. (A), expression level of PGAM1 mRNA was semi-quantified by RT-PCR. Pairs of the total mRNA were 
normalized by GAPDH. (B), representative results of Western blot analysis of HCCs and the adjacent noncancerous samples with β--actin as an internal 
control. (C), box chart, quantitative Western blot results of HCCs vs. the corresponding normal tissues. To ensure reproducibility, three independent 
experiments were performed. *, p < 0.01, Student's t test. N, normal liver tissue. C, cancer tissue.
Table 3: PGAM1 immunoreactivity in normal liver tissues and hepatocellular carcinoma tissues.
Histodifferentiation 
Grading
Cases -- + + + + + +a Total Score Average Scorea
Normal liver tissues 21 19% (4/21) 81% (17/21) 0 0 48 2.29 ± 1.02
Hepatocellular carcinoma 54 0 33% (18/54) 26% (14/54) 41% (22/54) 428 7.93 ± 2.58
a Student's t test, p < 0.01.Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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treated with PGAM1-shRNA-a. As shown in Fig 4C, a
clear-cut difference was observed at 72 h posttransfec-
tion, and the apoptosis/PI positive percentage reached
48.6% for PGAM1-shRNA-a treated cells compared with
1.0%, 1.2% and 7.8% for untreated, Lipofectamine 2000
and HK-shRNA, respectively (p < 0.01). As the sub-G1
values measured by flow cytometry represent dead cells
arising from both apoptosis and necrosis, a more specific
TUNEL assay was applied to measure the apoptotic cells
induced by PGAM1-shRNA-a. Cell nuclei with DNA
strand breaks were revealed by labeling free 3'-OH ter-
mini and observed to stain dark green as viewed by fluo-
rescence microscopy, indicating apoptosis, and were
recorded as TUNEL-positive nuclei. As shown in Fig. 4D,
a significant increase of TUNEL-positive nuclei was
observed in the PGAM1-shRNA-a transfected cells (73.7
± 2.01%), compared with the control groups, 2.4 ± 0.67%
(Untreated control), 10.2 ± 1.34% (Lipofectamine 2000),
and 15.8 ± 1.67% (NC-shRNA control) (Dunnett's t test, p
< 0.01). Collectively, data obtained from diverse experi-
ments demonstrated that suppression of PGAM1 expres-
sion resulted in massive liver cancer cell apoptosis.
To rule out the potential off-target effect, HepG2 cells
were treated with another PGAM1 specific shRNA
(PGAM1-shRNA-b). As shown in Fig. S2 (A-C) in addi-
tional file 1, treatment with PGAM1-shRNA-b in HepG2
cells resulted in remarkable inhibition of cell prolifera-
tion, and induction of apoptosis, which were evidenced
by the observations from MTT assay, clonogenic forma-
tion assay and TUNEL assay.
PGAM1-shRNA-a inhibited xenograft tumor growth in vivo
To extend the above findings, in vivo studies were per-
formed using HepG2 xenograft tumor bearing mice.
Tumor volumes were measured every 2 days during treat-
ment duration until animals were sacrificed, and no ani-
mal death or signs of possible toxicity were observed
during this period (data not shown) [34]. Although the
tumors of all mice were approximately equal in initial vol-
umes, significant differences in tumor growth were
observed upon treatment with PGAM1-shRNA-a. As
shown in Fig 5A, the average tumor volumes at the termi-
nation of the experiment were 515.65 ± 40.14, 455.58 ±
40.23, and 410.23 ± 34.16 mm3 for PBS, Lipofectamine
2000, and NC-shRNA, respectively (p > 0.05). In compar-
ison, tumor volumes in mice treated with PGAM1-
shRNA-a were 212.71 ± 24.28 mm3, which were on aver-
age over 58.7% smaller than those in controls treated with
PBS (Student's t  test,  p  < 0.01) (Fig. 5A). To validate
PGAM1-shRNA-a mediated suppression of PGAM1
expression, immunohistochemical analysis against anti-
PGAM1 antibody was performed to detect PGAM1
expression level in the tumor-bearing mice which had
been subjected to PGAM-shRNA treatment. As shown in
Fig. 5B, tail intravenous injections of PGAM-shRNA-a
r e s u l t e d  i n  m o r e  t h a n  7 5 %  s u p p r e s s i o n  o f  P G A M 1  i n
tumor-bearing mice, whilst no obvious difference could
be observed regarding the expression level of PGAM1 in
the control mice either treated with Lipofectamine 2000
or NC-shRNA, relative to injection with PBS.
As PGAM1 repression inhibited cancer cell growth and
induced remarkable apoptotic cell death in vitro, we have
particular interest to examine the potential function
underlying PGAM1-shRNA-a mediated anti-tumor
activity in vivo. To this end, tumor cell proliferation and
apoptosis were assessed by Ki-67 immunoreactivity anal-
ysis and TUNEL assay. As shown in Fig. 5B, Ki-67 posi-
tive nuclei were decreased over 68% for control with PBS
(Student's  t  test,  p  < 0.01). In contrast, TUNEL assay
showed a remarkably higher percentage of TUNEL posi-
tive nuclei in PGAM1-shRNA-a treated group, relative to
injection of PBS control. Our data suggested that sup-
p r e s s i o n  o f  P G A M 1  e x p r e s s i o n  m e d i a t e d  b y  P G A M 1 -
shRNA-a could significantly inhibit cell proliferation and
induce apoptosis in vivo.
Discussion
Hepatocellular carcinoma (HCC), one of the most com-
mon malignancies worldwide, remains a major health
problem with increasing incidence rates even to date
[4,35], and there is an urgent need to identify novel
molecular targets for diagnosis, prognosis and treatment
of HCC. In the current study, a SILAC-based quantitative
proteomics approach was applied to profile the altered
expressed proteins between HepG2 cells and L02 cells,
resulting in identification of 63 distinct proteins with
Table 4: Relevance of HCC characteristics to PGAM1 immunoreactivity: histodifferentiation to PGAM1.
Histodifferentiation Grading Cases -- + + + + + +a Total Score Average Scoreb
Well differentiated 11 0 73% (8/11) 18% (2/11) 9% (1/11) 63 5.73 ± 2.46
Moderately differentiated 28 0 36% (10/28) 39% (11/28) 25% (7/28) 217 7.75 ± 2.68
Poorly differentiated 15 0 0 7% (1/15) 93% (14/15) 148 9.87 ± 3.17
a Cross χ2 test, p < 0.01.
bOne-way ANOVA analysis, p < 0.05; LSD-t test, p < 0.05 (well versus moderately; well versus poorly; moderately versus poorly).Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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Figure 3 Immunohistochemical analysis indicated that overexpression of PGAM1 in HCCs was closely associated with the degree of differ-
entiation and the lower survival rates. (A), staining against PGAM1 confirmed significant differences between normal liver tissues and hepatocel-
lular carcinoma samples more likely to present poor differentiation (p < 0.05). a, normal liver tissue; b, well differentiated tissue; c, moderate 
differentiation; d, poor differentiation. a-d, representative HE staining; a'-d', expression of PGAM1 was examined by immunohistochemistry. a"-d", rep-
resentative insets of a'-d'. Original magnification, × 200. (B), Kaplan-Meier survival curves showed the correlation between higher levels of PGAM1 ex-
pression and lower survival rates (p < 0.05).Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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Figure 4 Suppression of PGAM1 by PGAM1-shRNA-a resulted in cell growth arrest and induced apparent apoptosis in vitro. (A) Evaluation 
of the antiproliferation effects using MTT assay. Inhibition of cell growth by siRNA against PGAM1 was in a duration-dependent manner and the pro-
liferation rate was decreased to 48.6% at 72 h posttransfection. (B) Survival rates of hepatoma cells were examined by colony formation assay. 24 h 
after transfection, cells were allowed to grow at a density of 300 cells/dish for additional two weeks before staining with Crystal Violet. (C) Flow cytom-
etry analysis was performed and the subdiploid peak increased after 72 h of transfection (p < 0.05). (D) Cell apoptosis was assessed by TUNEL assay 
which showed a remarkably greater percentage of TUMEL positive nuclei of the PGAM1-shRNA-a group vs. the control group. a, untreated; b, Lipo-
fectamine 2000; c, shNC; d, PGAM1-shRNA-a. Results represent the average of three independent experiments and data were shown as mean ± S.D.Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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Figure 5 Treatment with PGAM1-shRNA-a inhibited xenograft tumor growth and induced apoptosis in vivo. (A), tumor volume growth curve 
after tail intravenous injection for 20 days. PGAM1-shRNA-a treatment resulted in significantly decreased tumor growth compared with other control 
groups (p < 0.05). (B) & (C), a significant decrease of PGAM1 expression in tumor-bearing mice examined by immunohistochemical analysis (upper 
lane). Cell proliferation was obviously inhibited and apparent apoptosis was induced (p < 0.05). a, PBS; b, Lipofectamine 2000; c, shNC; d, PGAM1-shR-
NA-a. Data were shown as mean ± S.D.Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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altered expression, which were associated with cell
metabolism, proliferation and/or apoptosis. Among
them, Profilin1, a member of profilin family, also known
as PFN1, was ubiquitous and down-regulated more than
3-fold in HepG2 cells. As a tumor suppressor in breast
cancer cells, PFN1 was reported to be involved in multi-
ple cell behaviors, including cell adhesion, growth, prolif-
eration and signal transduction [36,37]. On the contrary,
some key enzymes participated in glycolytic pathway
were overexpressed in HepG2 cells, exemplified by eno-
lase, which catalysed the conversion of 2-phosphoglycer-
ate to phosphoenolpyruvate; Phosphoglycerate kinase 1
was overexpressed more than 18-fold which catalysed the
conversion of 1,3-bisphosphoglycerate to 3-phosphoglyc-
erate coupled with the generation of ATP . Most intrigu-
ingly, we found that phosphoglycerate mutase 1
(PGAM1) was shown an upregulation up to 6-fold. As an
enzyme in glycolysis, PGAM1 was ubiquitously expressed
in human, Bacillus stearothermophilus [38], Escherichia
coli [39], Entamoeba histolytica [40], et al, functions to
catalyze the interconversion of 3-phosphoglycerate and
2-phosphoglycerate with 2,3-bisphosphoglycerate (2,3-
BPG) [15,41]. A recent study revealed that PGAM1 was
overexpressed in breast cancer, and suppression PGAM1
expression displayed a profound antiproliferative effect,
underscoring its important role in carcinogenesis [14].
Obviously, more extensive investigations on the functions
of PGAM1 which was upregulated in HCC are required
to elucidate the role of PGAM1 in hepatocarcinogenesis.
As an intracellular hallmark of neoplasm, the increased
level of glycolysis enables cancer cells to survive despite
the poor conditions [42]. Fifty years ago, Otto Warburg
had demonstrated that cancer cells were oxygen-inde-
pendent for producing ATP, particularly in the hypoxic
tumor microenvironment [9,43]. Previous studies dem-
onstrated that hypoxia inducible factor (HIF) enhanced
glycolysis by increasing the transcription of glycolytic
enzyme genes to protect cancer cells from energy starva-
tion [44,45]. It has been clear that, highly proliferative
cancer cells need to synthesize fatty acids de novo to con-
tinually provide lipids for membrane production. An
increased glycolytic flux could lead to an augmented
amount of metabolic precursors for the synthesis of
nucleic acid, amino acid or lipid which are essential for
the cancer cell growth and proliferation [46,47]. Con-
versely, inhibition of glycolytic pathway results in
decreasing not only amino acid and lipid synthesis but
also ATP production. An increased AMP/ATP ratio is
important for activation of AMP-activated protein kinase
(AMPK). Once activated by energy starvation, AMPK
directly phosphorylates tuberous sclerosis complex 2
(TSC2) on T1227 and S1345, stimulates its GTPase activ-
ity resulting in the inhibition of Ras homologue enriched
in brain (Rheb) which is essential for mammalian target
of rapamycin (mTOR) activity. Moreover, inactivation of
mTOR was strongly correlated with cell growth arrest
and apoptosis [12]. On the other hand, acetyl-CoA car-
boxylase (ACC) is an important rate-controlling enzyme
for the synthesis of malonyl-CoA, which is not only a crit-
ical precursor for biosynthesis of fatty acids but also a
potent inhibitor of mitochondrial fatty acid oxidation. In
this case, phosphorylation and inhibition of ACC by
AMPK leads to a fall in malonyl-CoA content and a sub-
sequent decrease in triglyceride synthesis concomitantly
with an increase in β-oxidation [48]. In general, it has
bee n c ons ide r ed t ha t  gly c ol ys is  pla ys  a p ivota l r ole  f o r
ATP production and cell growth in transformed cells (Fig.
6). Considerable effort has been made to elucidate the
close correlation between rates of aerobic glycolysis and
t h e  d e g r e e  o f  m a l i g n a n c y  [ 4 9 ] .  I n  v i e w  o f  t h i s ,  t h e
decreased of glucose level should be strongly tumoricidal
for transformed cells proliferation [50]. For example, 3-
bromo pyruvate, an inhibitor of hexokinase, has been
demonstrated to inhibit glycolysis and effectively kill
hepatoma cells in tissue culture even at a lower concen-
tration [51]. Furthermore, in the presence of GAPDH,
Nm23-H1 could phosphorylate PGAM1 and inhibit
PGAM1 activity resulting in suppression of glycolysis and
inducing growth arrest in various cancer cells, including
glioblastoma cell line Tx3095, small lung cancer cell line
GLC4, beast carcinoma cell lines MCF-7 and MDA-MB-
453, etc [13]. Under this circumstance, PGAM1 should be
a potential diagnostic biomarker, as well as a therapeutic
target for various malignancies.
Clinico-pathological analysis indicated that overexpres-
sion of PGAM1 was associated with 66.7% HCC, and
strongly correlated with poor differentiation and
decreased survival rates (p < 0.01). Our studies suggested
that PGAM1 has the potential to be developed as a useful
diagnostic and prognostic marker for HCC. Further stud-
ies should be performed to evaluate if PGAM1 could be
utilized as an independent biomarker for early diagnosis
of HCC. On the other hand, silencing expression of
PGAM1 significantly induced liver cancer cell apoptosis
both in vitro and in vivo. Apoptosis is a major barrier that
must be circumvented during malignant transformation.
Cancer cells evolve to evade apoptosis so that they can
escape from being cleared away by the surveillance sys-
tem and can survive in the crucial tumor microenviron-
ment, such as hypoxia and nutrition depletion [52].
Defective apoptosis was considered as a major causative
factor in the genesis and development of many human
cancers, triggering tumor selective apoptosis in cancer
cells exploited into a promising strategy for clinical treat-
ment [53]. The strong apoptosis-promoting activities
mediated by PGAM1-siRNA suggested that PGAM1
would be an attractive drug target for therapeutic treat-
ment with HCC. Further intensive studies should be con-Ren et al. Molecular Cancer 2010, 9:81
http://www.molecular-cancer.com/content/9/1/81
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ducted to pinpoint the molecular mechanisms underlying
PGAM1-siRNA mediated cell death.
Conclusions
So far, a small but increasing number of reports were doc-
umented regarding targeting a cellular metabolic enzyme
for cancer therapy [54], thus the current study provided
new insights for potential clinical treatment of HCC
using siRNA-mediated suppression of PGAM1 expres-
sion since RNAi technology has emerged as a powerful
tool to silence gene expression in mammalian cells so that
i t  c o u l d  be  u s e d  t o  i n v e s t i g a t e  t h e  g e n e  f u n c t i o n  [ 5 5 ] .
Hopefully, shRNA-mediated suppression of PGAM1
expression, combined with conventional surgical resec-
tion and chemotherapy strategies, will open a new avenue
for clinical treatment of hepatocellular carcinoma.
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kinase; TSC, tuberous sclerosis complex; Rheb, Ras homologue enriched in brain; mTOR, mammalian target of rapamycin; S6K, ribosomal protein S6 
kinases; 4E-BP1, eIF4E-binding protein; ACC, acetyl-CoA carboxylase; FASN, fatty-acid synthase; CDKs, cyclin dependent kinases.Ren et al. Molecular Cancer 2010, 9:81
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